SCHEMBL10189883

SCHEMBL10189883

CCOCc1nnc(C2CCN(C(=O)OC(C)(C)C)CC2)o1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.54
THRB P10828 2/20 0.54
GAA P10253 2/20 0.54
MAPT P10636 3/20 0.51
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
TLR8 Q9NR97 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
RECQL P46063 1/20 0.40
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GPR119 Q8TDV5 4/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
FAAH O00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8250610 0.88 SMN1; SMN2 (0.56) SMN1; SMN2THRBGAAMAPTKDM4E
SCHEMBL10189881 0.88 SMN1; SMN2 (0.52) SMN1; SMN2THRBGAAMAPTKDM4E
SCHEMBL10189882 0.86 SMN1; SMN2 (0.58) SMN1; SMN2THRBGAAMAPTKDM4E
SCHEMBL315249 0.85 SMN1; SMN2 (0.57) SMN1; SMN2THRBGAAMAPTKDM4E
SCHEMBL314745 0.84 L3MBTL1 (0.41) SMN1; SMN2THRBGAAMAPTALDH1A1
SCHEMBL8283578 0.83 SMN1; SMN2 (0.55) SMN1; SMN2THRBGAAMAPTKDM4E
SCHEMBL16399632 0.83 SMN1; SMN2 (0.61) SMN1; SMN2THRBGAAMAPTKDM4E
SCHEMBL5217057 0.80 SMN1; SMN2 (0.52) SMN1; SMN2THRBGAAMAPTKDM4E
SCHEMBL316694 0.80 SMN1; SMN2 (0.55) SMN1; SMN2THRBGAAMAPTKDM4E
SCHEMBL314695 0.79 SMN1; SMN2 (0.58) SMN1; SMN2THRBGAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
US-7745630-B2 Triazolyl piperidine arginine vasopressin receptor modulators BRYANS JUSTIN STEPHEN 2010-06-29 US disclosed
US-7745630-B2 Triazolyl piperidine arginine vasopressin receptor modulators BRYANS JUSTIN STEPHEN 2010-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317652-A1 Compounds Useful In Therapy AVPR1A, AVPR1B, AVPR2 SMN1; SMN2 4519/4885THRB 1583/4885GAA 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.